(4- ((5,6- diphenylpyrazin- 2- yl)(isopropyl)amino)butoxy)acetic acid

active form of NS-304

Also Known As:

ACT-333679; MRE 269; MRE-269; MRE269

Networked: 7 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - (4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid: 7
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - (4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid: 7
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrazines: 150
    - (4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)acetic acid: 7

Experts

1.	Boehler, Margaux: 1 article (12/2017)
2.	Bruderer, Shirin: 1 article (12/2017)
3.	Dingemanse, Jasper: 1 article (12/2017)
4.	Halabi, Atef: 1 article (12/2017)
5.	Petersen-Sylla, Marc: 1 article (12/2017)
6.	Remeňová, Tatiana: 1 article (12/2017)
7.	Alexander, Jon C: 1 article (01/2017)
8.	Andersen, Asger: 1 article (01/2017)
9.	Bruderer, S: 1 article (01/2017)
10.	Bøtker, Hans Erik: 1 article (01/2017)

Related Diseases

1.	Pulmonary Arterial Hypertension 12/01/2012 - "The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). "
2.	Stroke (Strokes) 01/01/2017 - "We hypothesized that postischemic treatment with MRE-269 provides long-lasting neuroprotection with improved neurological outcomes in a clinically relevant rat stroke model. " 01/01/2017 - "Quantitative magnetic resonance imaging data showed that postischemic MRE-269 treatment significantly reduced infarct volume compared with vehicle-treated rats at both 48 hours and 3 weeks after stroke. "
3.	Pulmonary Hypertension 04/01/2023 - "Antiproliferative effect of selexipag active metabolite MRE-269 on pulmonary arterial smooth muscle cells from patients with chronic thromboembolic pulmonary hypertension." 12/01/2013 - "Prostacyclin (PGI2) and its mimetics (iloprost, treprostinil, beraprost and MRE-269) are potent vasodilators (via IP-receptor activation) and a major therapeutic intervention for pulmonary hypertension (PH). "
4.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2017 - "MRE-269 treatment resulted in a significant long-term recovery in both locomotor and somatosensory functions after middle cerebral artery occlusion, which was associated with a reduced weight loss in animals receiving the IP receptor agonist. " 01/01/2017 - "Aged male Sprague-Dawley rats underwent transient middle cerebral artery occlusion and were randomly selected to receive either vehicle or MRE-269 (0.25 mg/kg) intravenously starting at 4.5 hours post ischemia. "
5.	Weight Loss (Weight Reduction) 01/01/2017 - "MRE-269 treatment resulted in a significant long-term recovery in both locomotor and somatosensory functions after middle cerebral artery occlusion, which was associated with a reduced weight loss in animals receiving the IP receptor agonist. "

Related Drugs and Biologics

1.	treprostinil
2.	Vasodilator Agents (Vasodilators)
3.	selexipag
4.	Epoprostenol (Prostacyclin)
5.	Matrix Metalloproteinase 9 (Gelatinase B)
6.	Iloprost (Ventavis)
7.	Immunoglobulin G (IgG)
8.	beraprost